

---

## Alzheimer Europe Networking

From 6 to 8 October (Warsaw, Poland) AE Board, members and staff attended the Annual General Meeting and the 21<sup>st</sup> Alzheimer Europe Conference "European solidarity without borders".

On 11 October (Brussels, Belgium) Annette and Alex attended an Alzheimer's Society (UK) lunch debate in the European Parliament.

On 13 October (Esch/Alzette, Luxembourg) Jean gave a presentation on the activities of Alzheimer Europe at the 5<sup>th</sup> Networking Event of the Luxembourg BioHealth Community.

On 17-18 October (London, UK) Alex attended an IMI PharmaCog review.

On 20 October (Brussels, Belgium) Annette met Heinz K. Becker (MEP, Austria, EPP) to discuss the European Alzheimer's Alliance.

On 24-25 October (Brussels, Belgium) Annette attended the Horizontal Workshop organised by the European Commission on the European Innovation Partnership on Active and Healthy Ageing.

On 26-27 October (Rome, Italy) Alex attended a DECIDE project meeting.

---

### DECIDE

#### 3 October: Fulvio Galeazzi is appointed new DECIDE Project Manager



Mr Fulvio Galeazzi, Technology Researcher at GARR, became the new DECIDE Project Manager on 3 October. He replaces Ms Laura Leone.

Mr Galeazzi has been with GARR since 2010. Previously, he was involved with projects EUMEDGRID-Support and EUChinaGRID (2005-2009) and with the BaBar, ATLAS and Argo experiments (2002-2010). He holds a PhD in Physics from the University of Padova.

#### 6 October: DECIDE project team completes first annual review



The DECIDE project team completed its first annual review by European Commission experts on 6 October in Warsaw. Presentations by DECIDE team members included:

1. Mr Fulvio Galeazzi (Project Manager) introduced the project and outlined the first year's achievements.
2. Dr Giovanni Frisoni (Scientific Manager) demonstrated the clinical benefits of the use of imaging markers.
3. Ms Valeria Ardizzone (Technical Manager) described the grid infrastructure, middleware standards and data management services.

DECIDE has generated considerable interest in the European Commission. The technical and scientific aspects were examined in detail and proved their validity and scientific value. During the second project year, the DECIDE team will continue to work on these fronts and will also focus on:

- establishing user groups for service validation and testing
- developing user training programmes
- strategic planning to ensure that the service can reach the greatest number of users worldwide.

#### 7 October: DECIDE demonstrates algorithm to aid earlier diagnosis of Alzheimer's disease

The DECIDE project team demonstrated the potential of the GridSPM algorithm during a conference in Warsaw. This algorithm analyses brain perfusion and metabolism and provides a report containing a quantitative measure of the statistical deviation with respect to a set of normal cases. The report is delivered to researchers and doctors via the high-speed GÉANT network.

"DECIDE will ensure that the diagnostic process is much more straightforward and simple, using distributed computing resources and the power of the GÉANT network to create an advanced e-infrastructure that spans the entire European medical community" said Fulvio Galeazzi, DECIDE Project Manager.

### PharmaCog

#### 17 October: PharmaCog project team holds progress meeting

The PharmaCog project team held a pre-clinical and work package progress meeting on 17-18 October in Ascot, England.

More than 60 delegates attended the meeting, which was led by Mike O'Neill (Work Package 6 coordinator), Dr. Jill Richardson (EFPIA Coordinator) and Dr. Alexandra Auffret (Academic Coordinator).

The team concentrated on updates of Work Packages 1-8, in preparation for an annual review which will be published in February 2012. PharmaCog is approaching the end of the second year of a five year project life.



#### 24 October: Jean de Barry will lead Work Package 6 for PharmaCog

Jean de Barry will replace Phil Verwaerde as leader of Work Package 6, which deals with the characterisation of transgenics and marker development. Dr. de Barry (PhD, Chemical Engineering) is the scientific advisor of IHD and a senior researcher at Inserm.